DiSaia P J, Rich W M
Am J Obstet Gynecol. 1979 Dec 1;135(7):907-16. doi: 10.1016/0002-9378(79)90817-2.
Immunotherapy with nonspecific immunopotentiators such as Corynebacterium parvum is under study in several areas of gynecologic oncology. The efficacy of this new modality awaits the results of carefully done clinical trials designed to measure an improved effect on survival when this and similar agents are added to conventional therapy. This report deals with an attempt to demonstrate enhancement of the cell-mediated immune response in a small number of patients with advanced ovarian (18 patients) and cervical (12 patients) cancer who were treated with intravenous C. parvum in addition to either chemotherapy (Alkeran) or pelvic radiotherapy. Monitoring of the immune response was accomplished by skin testing, T-lymphocyte rosettes, B-lymphocyte rosettes, simulation of lymphocytes with mitogens (PHA and Con-A) and total lymphocyte counts. No distinct improvement in these parameters could be demonstrated as a result of immunotherapy with C. parvum. These results and the value of immune monitoring as currently performed are discussed.
使用诸如短小棒状杆菌等非特异性免疫增强剂进行免疫治疗正在妇科肿瘤学的多个领域进行研究。这种新方法的疗效有待精心设计的临床试验结果，这些试验旨在衡量当将这种及类似药物添加到传统治疗中时对生存率的改善效果。本报告涉及一项尝试，即在少数晚期卵巢癌（18例患者）和宫颈癌（12例患者）患者中，除了化疗（马法兰）或盆腔放疗外，还静脉注射短小棒状杆菌，以证明细胞介导的免疫反应增强。通过皮肤试验、T淋巴细胞玫瑰花结试验、B淋巴细胞玫瑰花结试验、用丝裂原（PHA和Con - A）刺激淋巴细胞以及总淋巴细胞计数来监测免疫反应。短小棒状杆菌免疫治疗并未显示出这些参数有明显改善。讨论了这些结果以及当前进行的免疫监测的价值。
